Medarex, Bristol-Myers deal

The companies partnered to develop MEDX's MDX-010 anti- CTLA-4 antibody and MDX-1379 gp100 peptide vaccine to treat melanoma.

Read the full 189 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE